SYMNET: A STUDY OF PATIENT-REPORTED OUTCOMES (PROS) ASSOCIATED WITH LANREOTIDE AUTOGEL (LAN)FOR THE CONTROL OF CARCIONID SYNDROME (CS) SYMPTOMS IN GASTROENTEROPATIC NEUROENDOCRINE TUMOR (GEP-NET)PATIENTS

Background:

Somatostatin analogs are known to reduce incidence/ severity of CS symptoms but how this impacts patients’ satisfaction needs further investigation.

Aim:

To assess PROs during LAN treatment of CS in GEP-NET patients.

Materials and methods:

At routine clinic visit, patients with CS-related diarrhea treated with LAN for > 3 mo comleted PRO questionnaries on satisfaction and symptom associated with CS control. Investigators also assessed patient characteristics as predictors for satisfaction.

Results:

Of 273 patients enrolled, 56% were male, 57% were aged > 60 yrs, 66% had small bowel primary tumors, and 80% had liver metastases. Prior to the study, 66% had surgery and 23% other anti-tumor therapy within last 3 mo. Mean time since diagnosis was 4.4 yrs. Mean LAN treatment duration was 21.7 mo and median dose 120 mg/ mo on study day. Most patients (76%) were satisfied with diarrhea control, and flushing control (73%). More patients indicated no, minimal, or mild diarrhea at study visit than before treatment (75 vs 33%). Most (79%) patients reported diarrhea was improved overall with LAN. Investigators identified a clinically relevant decrease in stool frequency since treatment initiation (median 4 to 2/ day). Statistically significant decreases (McNemar paired tests, p < 0.001) were seen in no. of patients with urgency (73 – 41%), leakage (21 – 9%), and associated pain (37 – 4%). Predictors of satisfaction with diarrhea control were initial stool leakage and non-small bowel primary localization.

Conclusions:

GEP-NET patients reported favourable control of CS symptoms with LAN treatment. Improvements in PROs were consistent with those on investigators' medical assessments. Factor identified as associated with satisfaction may help identify patients who most benefit from LAN.

Supported by the project CZ 1.05/ 2.1.00/ 03.0076 from European Regional Development Fund.